Effects of tacrolimus on proteinuria in Chinese and Indian patients with idiopathic membranous nephropathy: the results of machine learning study
- PMID: 38642210
- DOI: 10.1007/s11255-024-04056-y
Effects of tacrolimus on proteinuria in Chinese and Indian patients with idiopathic membranous nephropathy: the results of machine learning study
Abstract
Purpose: The present study aims to explore the effects of tacrolimus on proteinuria in patients with idiopathic membranous nephropathy (IMN) and recommend an appropriate dosage schedule via machine learning method.
Methods: The Emax model was constructed to analyze the effects of tacrolimus on proteinuria in patients with IMN. Data were mined from published literature and machine learning was built up with Emax model, among which the efficacy indicator was proteinuria change rates from baseline. 463 IMN patients were included for modeling, and tacrolimus therapeutic window concentrations were 4-10 ng/ml.
Results: In machine learning model, the Emax from tacrolimus effecting proteinuria in IMN patients was -72.7%, the ET50 was 0.43 months, and the time to achieving 25% Emax, 50% Emax, 75% Emax, and 80% (plateau) Emax of tacrolimus on proteinuria in patients with IMN were 0.15, 0.43, 1.29, and 1.72 months, respectively.
Conclusion: For achieving better therapeutic effects from tacrolimus on proteinuria in patients with IMN, tacrolimus concentration range need to be maintained at 4-10 ng/ml for at least 1.72 months.
Keywords: Idiopathic membranous nephropathy; Machine learning; Prediction; Proteinuria; Tacrolimus.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Tacrolimus in resistant primary membranous nephropathy--a report of 3 cases.Clin Nephrol. 2003 Apr;59(4):293-6. doi: 10.5414/cnp59293. Clin Nephrol. 2003. PMID: 12708570
-
Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.J Formos Med Assoc. 2016 Jan;115(1):11-8. doi: 10.1016/j.jfma.2015.07.021. Epub 2015 Aug 24. J Formos Med Assoc. 2016. PMID: 26315481 Clinical Trial.
-
The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.Ren Fail. 2017 Nov;39(1):512-518. doi: 10.1080/0886022X.2017.1325371. Ren Fail. 2017. PMID: 28562168 Free PMC article. Clinical Trial.
-
Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials.Ren Fail. 2021 Dec;43(1):840-850. doi: 10.1080/0886022X.2021.1914655. Ren Fail. 2021. PMID: 34016023 Free PMC article.
-
An overview of immunosuppressive therapy in idiopathic membranous nephropathy.Minerva Med. 2012 Aug;103(4):253-66. Minerva Med. 2012. PMID: 22805618 Review.
References
-
- Beck LH Jr, Salant DJ (2014) Membranous nephropathy: from models to man. J Clin Investig 124(6):2307–2314. https://doi.org/10.1172/JCI72270 - DOI - PubMed - PMC
-
- Huang H, Liang Z, Zheng X, Qing Q, Du X, Tang Z et al (2021) Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials. Ren Fail 43(1):840–850. https://doi.org/10.1080/0886022X.2021.1914655 - DOI - PubMed - PMC
-
- Zhang XD, Cui Z, Zhang MF, Wang J, Zhang YM, Qu Z et al (2018) Clinical implications of pathological features of primary membranous nephropathy. BMC Nephrol 19(1):215. https://doi.org/10.1186/s12882-018-1011-5 - DOI - PubMed - PMC
-
- Polanco N, Gutierrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D et al (2012) Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transpl 27(1):231–234. https://doi.org/10.1093/ndt/gfr285 - DOI
-
- Hladunewich MA, Troyanov S, Calafati J, Cattran DC (2009) The natural history of the non nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol CJASN 4(9):1417–1422. https://doi.org/10.2215/CJN.01330209 - DOI - PubMed
MeSH terms
Substances
Supplementary concepts
Grants and funding
- KC23254/The Xuzhou Special fund for promoting scientific and technological innovation
- RC20552111/The Initializing Fund of Xuzhou Medical University
- RC20552222/The Initializing Fund of Xuzhou Medical University
- XYRHCX2021011/Innovation Program in Military Medicine of Chinese People's Liberation Army
- XYRHCX2022005/The Fusion Innovation Project of Xuzhou Medical University
LinkOut - more resources
Full Text Sources